Quick answer
KDSTEM inj. is EHL Bio's cell therapy candidate using the patient's own urine-derived mesenchymal stem cells, given as repeat intravenous infusions for chronic kidney disease. Its scientific hook is that these cells express Klotho, an anti-ageing protein with antioxidant, anti-senescence, angiogenic and metabolic-regulating roles. It sits in preclinical and early clinical development.
Urine-derived cells: a non-invasive source
Collecting cells from urine is entirely non-invasive, unlike liposuction or bone marrow aspiration. The patient simply provides a urine sample and the lab isolates urothelial-lineage cells with stem cell properties for expansion.
The Klotho protein and kidney protection
Klotho is produced mainly in the kidney and its levels typically fall in chronic kidney disease. The mechanistic hypothesis is that cells expressing high Klotho may reduce oxidative stress and renal fibrosis — the two engines of progressive kidney decline.
Not yet standard care for chronic kidney disease
It must be stressed that KDSTEM is not standard care for CKD. Guideline therapy remains blood pressure and diabetes control, ACEi/ARB and SGLT2 inhibitors, plus stage-appropriate diet. Patients should never stop existing medication to pursue cell therapy.
Use the kidney planner before your consultation
If you are exploring options, our site's kidney planning tool estimates CKD stage from eGFR or creatinine and drafts a preliminary plan with questions to raise with your doctor. Always have your nephrologist review that plan before acting on it.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.